MATTHEW CARY: Open Payments
NPI 1619233525 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,549 in 123 payments from 16 companies in 2025. Trend: 2023 $2,197 · 2024 $7,865 · 2025 $3,549
Food & beverage: $2,461Travel & lodging: $1,087
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company | 49 | $1,872 |
| Gilead Sciences, Inc. | 23 | $693 |
| Lilly USA, LLC | 13 | $256 |
| AstraZeneca Pharmaceuticals LP | 8 | $157 |
| Amgen Inc. | 6 | $103 |
| Merck Sharp & Dohme LLC | 3 | $88 |
| Novo Nordisk Inc | 5 | $76 |
| Theratechnologies Inc. | 3 | $59 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $58 |
| ABBVIE INC. | 2 | $51 |
Products named: APRETUDE, MOUNJARO, Biktarvy, DOVATO, CABENUVA, OTEZLA, BREZTRI, PIFELTRO.
Industry payments across MO — which companies pay providers there.
